Neol Bio goes public on the MAB
Neol Bio, dedicated to the development of innovative microbial industrial biotechnology processes, debuted on the Alternative Stock Market (MAB) at the end of November.
The president of Neol Bio, José Manuel Arrojo, said that joining the MAB provides the company with "financing channels to guarantee the growth of the company for the new phase of development in which it finds itself, thanks to the notoriety that this market provides and the transparency and rigour that it demands". The sectors in which we operate; Oleochemicals, Omega-3 DHA and Bioenergy, and the technologies we develop will allow us, with the right financing, to multiply the size and value of Neol Bio several times over".
Oryzon is in the final stages of its IPO
Oryzonwhich researches diseases such as leukaemia and Alzheimer's, wants to go public before Christmas, although it says it does not rule out delays. The company's valuation will be €96M and a price per share of €3.39.
"As we already communicated in a previous post, Oryzon has recently received a €16.5M round to prepare for the IPO" says Diego Gutierrez of Oryzon. Abra-Invest.
In addition, the company sees the IPO as a stepping stone to the American market.
Oryzon achieved a net profit of €6.6 million in 2014, with record revenues of €13.1 million after signing its first licensing agreement with multinational Roche for €$21M and development milestones of up to €500M for its OLY1001 molecule for acute myeloid leukaemia.
Transplant biomedical raises €1.5M
Transplant biomedical has closed a €1.5M round which was led by Kereon Partners, and in which he has also participated Caixa Capital Risc.
The Barcelona-based company is developing an innovative medical device for the preservation and transport of abdominal and thoracic organs for transplantation. The funds raised in the round will be used to accelerate the development and commercialisation of this device.
The company intends to start marketing the system between 2017 and 2018.
"This device would improve post-transplant outcomes and lead to a better use of available organs and therefore to a reduction in the mortality of patients awaiting transplantation, as it would maintain the abdominal organs in better condition than at present during transport (cold ischaemia), thus increasing the viability of such grafts prior to transplantation.e"says Dr Joan Rodés, president of the Institut d'Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS) and member of the company's Scientific Advisory Board.
If you are looking for funding, please contact us. Abra-Invest has an expert team in alternative financing at your disposal with many years of experience in the biotech sector. Fill in the contact form or call us on + 34 946424142
Other posts that may interest you
October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics Spanish biotechs go international: Artax Biopharma, PharmaMar and Mind The Byte.
EN 
ES